Your browser is no longer supported. Please, upgrade your browser.
Settings
ALNY Alnylam Pharmaceuticals, Inc. daily Stock Chart
ALNY [NASD]
Alnylam Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-7.57 Insider Own0.20% Shs Outstand110.09M Perf Week-6.84%
Market Cap9.04B Forward P/E- EPS next Y-6.90 Insider Trans-6.38% Shs Float94.96M Perf Month-7.45%
Income-762.30M PEG- EPS next Q-2.07 Inst Own88.20% Short Float5.63% Perf Quarter1.72%
Sales74.90M P/S120.63 EPS this Y-39.80% Inst Trans-0.01% Short Ratio7.03 Perf Half Y-1.01%
Book/sh12.88 P/B6.37 EPS next Y19.40% ROA-43.70% Target Price123.72 Perf Year-16.00%
Cash/sh9.85 P/C8.33 EPS next 5Y46.09% ROE-49.50% 52W Range60.27 - 124.21 Perf YTD12.56%
Dividend- P/FCF- EPS past 5Y-39.20% ROI-59.70% 52W High-33.93% Beta2.55
Dividend %- Quick Ratio6.60 Sales past 5Y9.70% Gross Margin97.60% 52W Low36.17% ATR3.93
Employees1065 Current Ratio6.70 Sales Q/Q-44.60% Oper. Margin- RSI (14)39.48 Volatility5.36% 4.38%
OptionableYes Debt/Eq0.02 EPS Q/Q-41.40% Profit Margin- Rel Volume1.79 Prev Close84.89
ShortableYes LT Debt/Eq0.02 EarningsMay 02 AMC Payout- Avg Volume760.79K Price82.07
Recom2.00 SMA20-8.18% SMA50-4.88% SMA200-5.96% Volume1,359,385 Change-3.32%
Apr-12-19Initiated Evercore ISI Outperform
Mar-06-19Upgrade Evercore ISI In-line → Outperform
Mar-05-19Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-23-19Initiated UBS Neutral $87
Oct-01-18Initiated Cantor Fitzgerald Overweight $135
Aug-13-18Reiterated Stifel Buy $125 → $123
Aug-07-18Upgrade Stifel Hold → Buy $95 → $125
May-04-18Reiterated Stifel Hold $107 → $95
Mar-28-18Initiated Evercore ISI In-line
Mar-26-18Reiterated JMP Securities Mkt Outperform $169 → $207
Feb-16-18Reiterated B. Riley FBR, Inc. Buy $205 → $200
Jan-08-18Reiterated B. Riley FBR, Inc. Buy $220 → $205
Nov-09-17Upgrade JP Morgan Neutral → Overweight
Nov-08-17Reiterated Barclays Overweight $127 → $158
Nov-08-17Reiterated B. Riley FBR, Inc. Buy $240 → $220
Nov-03-17Reiterated Needham Buy $125 → $152
Nov-02-17Reiterated B. Riley FBR, Inc. Buy $150 → $240
Oct-30-17Initiated FBR & Co. Buy $150
Oct-02-17Upgrade Goldman Neutral → Buy
Sep-21-17Reiterated Needham Buy $85 → $125
Apr-19-19 10:41AM  Here is What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. (ALNY) Insider Monkey
Apr-16-19 07:13PM  Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran Zacks
07:27AM  Is Alnylam Pharmaceuticals a Buy Now? Motley Fool
Apr-15-19 04:49PM  Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran Zacks
07:00AM  Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study Business Wire
Apr-12-19 06:01PM  Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria Business Wire
07:23AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Apr-11-19 09:27AM  4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics Zacks
Apr-10-19 09:20AM  Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More Zacks
Apr-09-19 09:03AM  Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics Zacks
Apr-08-19 01:55PM  Regeneron, Alnylam Strike $1B Collaboration For RNAi-based Therapeutics Benzinga
11:13AM  Regeneron forays into gene-silencing therapies with Alnylam tie-up Reuters
09:10AM  Alnylam trades partner Sanofi for Regeneron in $800M deal American City Business Journals
08:50AM  What Do Analysts Think About Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Earnings Trajectory? Simply Wall St.
07:11AM  Alnylam, Regeneron to partner for RNAi treatments Reuters
07:00AM  Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases PR Newswire
07:00AM  Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases Business Wire
01:00AM  Alnylam and Sanofi Conclude Research and Option Phase of 2014 RNAi Therapeutics Collaboration Business Wire
Mar-30-19 11:31AM  2 Biotechs With Big Dates in April Motley Fool
Mar-27-19 07:00AM  Alnylam to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver (EASL) International Liver Congress Business Wire
Mar-20-19 07:07AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Mar-18-19 06:51PM  Alnylam's (ALNY) Impressive Pipeline Drives Share Price Zacks
Mar-12-19 09:59AM  Alnylam Files Application for Hypertension Candidate in UK Zacks
Mar-11-19 07:00AM  Alnylam Submits CTA Application for ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension in High Unmet Need Settings Business Wire +5.50%
Mar-09-19 08:31AM  Why Is Alnylam (ALNY) Up 3.1% Since Last Earnings Report? Zacks
Mar-07-19 04:00PM  Alnylam to Webcast Presentation at Cowen & Company 39th Annual Health Care Conference Business Wire
09:00AM  Alnylam Stock Down Despite Positive Phase III Givosiran Data Zacks
Mar-06-19 04:10PM  Could This Biotech Sacrifice A Buy Point On Drug Safety Questions? Investor's Business Daily
11:06AM  Side effects of Alnylam's gene-silencing drug raise concerns, shares slip Reuters
09:12AM  Alnylam Pharmaceuticals stock down 7.5% after announcing results of Phase 3 givosiran trial MarketWatch
08:20AM  After trial success, Alnylam plans to seek FDA approval for 2nd drug American City Business Journals
07:08AM  Alnylam's gene-silencing drug meets main goal in late-stage study Reuters
07:00AM  Alnylam Reports Positive Topline Results from ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria Business Wire
Mar-04-19 09:19AM  Can This Biotech Puppy Run With the Big Dogs? Motley Fool
Feb-28-19 09:50AM  Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus Zacks
07:00AM  Alnylam Announces Recipients of First Annual Advocacy for Impact Grants Program Business Wire
Feb-25-19 06:43AM  FDA panel says Karyopharm's cancer drug shows 'significant toxicity' American City Business Journals
Feb-14-19 06:48PM  Alnylam Pharmaceuticals Inc (ALNY) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
12:01PM  Is Moderna a Buy? Motley Fool
Feb-12-19 10:04AM  Alnylam Pharmaceuticals Is Launched and Ready for More Motley Fool
08:10AM  Detailed Research: Economic Perspectives on DXC Technology, AMC Networks, SunCoke Energy Partners, Alnylam Pharmaceuticals, Amtech, and Diamond Hill Investment Group What Drives Growth in Today's Competitive Landscape GlobeNewswire
Feb-11-19 11:14AM  Edited Transcript of ALNY earnings conference call or presentation 7-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-08-19 09:17AM  The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs Benzinga
07:47AM  Alnylam's (ALNY) Q4 Earnings and Revenues Beat Estimates Zacks
Feb-07-19 11:15PM  Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:15PM  Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates Zacks
05:23PM  Alnylam: 4Q Earnings Snapshot Associated Press
04:00PM  Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity Business Wire
Feb-06-19 05:00PM  Alnylam Announces Publication of Phase 1 Givosiran Data in The New England Journal of Medicine Business Wire
Feb-04-19 04:00PM  Alnylam to Webcast Presentations at Upcoming February Investor Conferences Business Wire
Jan-31-19 04:00PM  Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2018 Financial Results Business Wire
07:55AM  Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sarepta Therapeutics ACCESSWIRE
Jan-24-19 10:51AM  The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio Zacks
Jan-23-19 10:48AM  5 Best Biotech Bets Likely to Outperform Estimates in Q4 Zacks
09:12AM  Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs Zacks
Jan-22-19 07:58AM  Alnylam & Medison Partner to Market RNAi Products in Israel Zacks
Jan-21-19 03:00AM  Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel Business Wire
Jan-16-19 07:30AM  New Research Coverage Highlights Gentex, Tenneco, Mercury General, MGM Resorts International, ResMed, and Alnylam Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Jan-15-19 08:00AM  Pfizer Gets FDA's Priority Review for Rare Disease Candidate Zacks
Jan-14-19 09:13PM  Alnylam Pharmaceuticals Prices Public Offering of Common Stock Business Wire -5.72%
04:23PM  This Biotech Stock Plunged On Its Looming Rivalry With Pfizer Investor's Business Daily
04:04PM  Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
Jan-09-19 09:33AM  Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus Zacks
Jan-08-19 04:52PM  3 Things Alnylam's Management Wants You to Know Motley Fool
09:54AM  Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4 Zacks
Jan-07-19 09:58AM  Sales of Alnylam's first drug beat expectations in final quarter of 2018 American City Business Journals +8.75%
08:00AM  Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues for ONPATTRO® (patisiran) and Provides Additional Commercial Updates Business Wire
Jan-02-19 03:48PM  Cannabis, Migraines, Gene-Silencing: FDA Approvals Hit High Note In 2018 Investor's Business Daily
Dec-28-18 07:00AM  Alnylam to Webcast Presentation at 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-27-18 08:37AM  Alnylam (ALNY) Surges: Stock Moves 8.7% Higher Zacks
Dec-20-18 05:13PM  Robbins Arroyo LLP: Alnylam Pharmaceuticals, Inc. (ALNY) Sued by Shareholders Business Wire
Dec-18-18 09:29AM  RNAi Goes Big-Time in 2018 Motley Fool
08:55AM  Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved Benzinga
Dec-13-18 10:13AM  Top 10 Healthcare Stories of 2018 Motley Fool
07:00AM  Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Array BioPharma ACCESSWIRE
Dec-10-18 07:58AM  5 Top Drug/Biotech Merger & Acquisition Targets for 2019 Zacks
02:00AM  Alnylam Announces Settlement of Litigation with Silence Therapeutics Business Wire
Dec-08-18 12:44PM  Hedge Funds Are Dumping Alnylam Pharmaceuticals, Inc. (ALNY) Insider Monkey
Dec-07-18 06:11PM  [$$] Moderna IPO Marks Milestone for New Biotech Market The Wall Street Journal -6.71%
12:20PM  Modernas Rich IPO Valuation Raises the Stakes for Investors Bloomberg
Dec-06-18 08:15AM  Recent Analysis Shows Microsoft, Alnylam Pharmaceuticals, F5 Networks, Green Plains Partners LP, Itron, and Progress Software Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
07:00AM  Alnylam Provides R&D Updates and Announces 2019 Product and Pipeline Goals at R&D Day Business Wire
Nov-30-18 06:55AM  Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sage Therapeutics ACCESSWIRE
Nov-29-18 05:30PM  Why Pfizer Could Lead These Two Biotech Stocks In Tackling Amyloidosis Investor's Business Daily
03:28PM  Alnylam CEO on drug prices: Has to be some type of reward... CNBC Videos
08:00AM  Alnylam to Webcast R&D Day Business Wire
Nov-27-18 03:41PM  Alnylam, Vir Begin Phase I/II Study on Hepatitis B Candidate Zacks
02:48PM  Why Alnylam Pharmaceuticals Incs (NASDAQ:ALNY) CEO Pay Matters To You Simply Wall St.
Nov-26-18 10:00AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) & Lead Plaintiff Deadline November 26, 2018 GlobeNewswire +6.83%
08:00AM  DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
07:00AM  Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218 Business Wire
Nov-25-18 06:07PM  DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
10:17AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TGTX, ALNY, CHGG, CWH and DY GlobeNewswire
09:00AM  ALNY NOV 26 DEADLINE: Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important Deadline in Class Action GlobeNewswire
08:00AM  MONDAY DEADLINE: Kaskela Law LLC Announces Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ALNY GlobeNewswire
Nov-24-18 06:42PM  TUESDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
01:50PM  SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. ALNY ACCESSWIRE
Nov-23-18 11:41AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm ACCESSWIRE
10:30AM  DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:00AM  SHAREHOLDER ALERT: APOG TGTX ALNY ACHC JT HON DY ALGN RYAAY MGI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company's development programs include Vutrisiran, an investigational RNAi therapeutic targeting transthyretin that is in Phase III trials for the treatment of transthyretin-mediated amyloidosis; Givosiran that is in Phase III trials to treat acute hepatic porphyrias; and Lumasiran, an investigational RNAi therapeutic, which is in Phase III clinical trials for glycolate oxidase to treat primary hyperoxaluria type 1. It is also developing Inclisiran, an investigational RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9 that is in Phase III clinical trials for the treatment of hypercholesterolemia; and Fitusiran, an investigational RNAi therapeutic that is in Phase III clinical trials for treating hemophilia A and B with or without inhibitors. In addition, the company engages in the development of Cemdisiran for complement-mediated diseases; ALN-AAT02 to treat alpha-1 anti-trypsin deficiency-associated liver disease; ALN-HBV02 for treating chronic hepatitis B virus infection; and other earlier-stage programs. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHARP PHILIP ADirectorApr 15Option Exercise22.0915,000331,350250,633Apr 17 04:05 PM
SHARP PHILIP ADirectorApr 15Sale88.2315,0001,323,442235,633Apr 17 04:05 PM
MARAGANORE JOHNChief Executive OfficerNov 21Option Exercise21.3598,6362,105,879249,933Nov 26 04:11 PM
Greenstreet YvonneEVP, Chief Operating OfficerAug 30Sale120.002,500300,0001,916Sep 04 04:15 PM
MARAGANORE JOHNChief Executive OfficerJul 25Option Exercise21.3550,0001,067,500201,297Jul 27 04:07 PM
MARAGANORE JOHNChief Executive OfficerJul 25Sale105.3950,0005,269,457151,297Jul 27 04:07 PM
KEATING LAURIESVP, GC & SecretaryJun 20Option Exercise42.221,56365,99016,063Jun 22 04:20 PM
KEATING LAURIESVP, GC & SecretaryJun 20Sale105.041,563164,17814,500Jun 22 04:20 PM
CLARKE JOHN KDirectorMay 31Option Exercise27.2815,000409,20023,891Jun 04 04:25 PM
CLARKE JOHN KDirectorMay 31Sale100.3115,0001,504,6788,891Jun 04 04:25 PM